Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2

• Published in: Cancer letters Vol. 396; pp. 66 - 75
• Main Authors: Zhang, Chun-Lin, Zhu, Kun-Peng, Ma, Xiao-Long
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 28.06.2017; Elsevier Limited
• Subjects: Adolescent; Adult; Antibiotics, Antineoplastic - pharmacology; Antisense RNA; Antisense-lncRNA; Bone cancer; Bone Neoplasms - drug therapy; Bone Neoplasms - genetics; Bone Neoplasms - metabolism; Cancer; Cell Line, Tumor; Chemotherapy; Child; Cytoplasm; Double-stranded RNA; Doxorubicin; Doxorubicin - pharmacology; Doxorubicin resistance; Drug resistance; Drug Resistance, Neoplasm; Female; Forkhead Transcription Factors - biosynthesis; Forkhead Transcription Factors - genetics; Forkhead Transcription Factors - metabolism; FOXC2-AS1; Gene expression; Hematology, Oncology and Palliative Medicine; Humans; Male; Multidrug resistance; Osteosarcoma; Osteosarcoma - drug therapy; Osteosarcoma - genetics; Osteosarcoma - metabolism; Post-transcription; Proteins; Ribonucleic acid; RNA; RNA, Long Noncoding - genetics; RNA, Long Noncoding - metabolism; Rodents; Sarcoma; Transcription factors; Young Adult; FOXC2-AS1; Antisense-lncRNA; Osteosarcoma; Doxorubicin resistance; doxorubicin resistance; osteosarcoma

Recent efforts have revealed that numerous natural antisense lncRNAs play a crucial role in the regulation of cancer biology. Here, based on our previous study, we further identified that the lncRNA FOXC2-AS1 and its antisense transcript FOXC2 are positively up-regulated in doxorubicin-resistant ost...